🕒 Last update: loading…

Stock VivoSim Labs, Inc. VIVS

VivoSim Labs, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2025 → 2026: -88.54%

Price change 2026 (year to date): -88.96%

Financial growth

Revenue CAGR (8 years): -36.34%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 447000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.04

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 87.87% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
VivoSim Labs, Inc.–0.09–🔒
Spineway S.A.–0.07+9.3 %–
CompuMed, Inc.–0.23+10.2 %–
SpineGuard S.A.–0.27+1.6 %–
Aelis Farma S.A.–1.49+49.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by VivoSim Labs, Inc. over the latest fiscal years.

Revenue
131,000 USD
fiscal year 2026
Net income
-13.8 m USD
fiscal year 2026
Net margin
-10,567.2 %
fiscal year 2026
Average annual growth
-43.1 %
Revenue growth over 5 years
Average annual growth
-13.7 %
Revenue growth over 10 years
Market cap
2.1 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20202.2 m-18.7 m-852.0 %n/a
20221.5 m-11.4 m-763.2 %-31.7 %
2023370,000-17.3 m-4,664.6 %-75.3 %
2024109,000-14.7 m-13,459.6 %-70.5 %
2025144,000-2.5 m-1,727.8 %+32.1 %
2026131,000-13.8 m-10,567.2 %-9.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by VivoSim Labs, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-52.62
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.80 x
low debt
Fiscal year20222023202420252026
Cash and investments28.7 m16.0 m2.9 m11.3 m5.0 m
Total Debt2.2 m1.8 m1.4 m942,000447,000
Net Debt-26.5 m-13.5 m-1.5 m-10.4 m-4.6 m
Equity30.2 m15.3 m3.6 m10.5 m-1.1 m
Total assets33.3 m20.3 m6.3 m14.7 m7.4 m
Operating cash flow-8.5 m-12.4 m-14.7 m-9.5 m-10.8 m
Investments (capex)409,000396,00042,00013,0000
Free cash-flow-8.9 m-12.8 m-14.7 m-9.5 m-10.8 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.07 x
Price / book value0.66 x
Return on Equity (ROE)-498.6 %
Return on Invested Capital (ROIC)-154.9 %
Net margin-7,605.9 %
Debt / equity0.07 x
Current ratio3.50 x
Interest coverage-1,001.00 x
Free cash-flow yield-212.7 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

VivoSim Labs, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
VivoSim Labs, Inc.2.3 mn/a-1,727.8 %
Quoin Pharmaceuticals, Ltd. QNRX7.3 mn/a0.0 %
Pasithea Therapeutics Corp. KTTA19.3 mn/a0.0 %
Alaunos Therapeutics, Inc. TCRT6.0 mn/a-83,520.0 %
PharmaCyte Biotech, Inc. PMCB3.9 mn/a0.0 %
Polyrizon Ltd. PLRZ12.4 mn/a0.0 %
Radiopharm Theranostics Limited RADX1.2 mn/a-273.9 %
XTL Biopharmaceuticals Ltd. XTLB1.5 mn/a0.0 %
Impact BioMedical Inc. IBO35.5 mn/a-36,993.8 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

VivoSim Labs, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
14/07/2026-2.21-2.04n/a
11/02/2026-1.03-2.40n/a
06/11/2025-0.98-2.28n/a
30/05/2025-3.48-2.28n/a
19/02/2025-0.19-2.52n/a
08/11/2024-1.68-3.12n/a

Stock splits

DateOperation
21/03/2025reverse split: 1 share for 12
19/08/2020reverse split: 1 share for 20

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in VivoSim Labs, Inc.

Free float
83.4 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 14/02/2012
ISIN code
US68620A3023
Workforce
14
full-time employees
Chief executive
Keith E. Murphy

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about VivoSim Labs, Inc.

What is the VivoSim Labs, Inc. share price?

Latest recorded price: 0.127 USD on 13/11/2026, for a market cap of 2.1 m USD.

What is the revenue of VivoSim Labs, Inc.?

131,000 USD for fiscal year 2026, with net income of -13.8 m USD (net margin -10,567.2 %).

Is VivoSim Labs, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US68620A3023).

How many employees does VivoSim Labs, Inc. have?

14 full-time employees according to the latest published profile.

Who runs VivoSim Labs, Inc.?

Keith E. Murphy is the company's chief executive.

07

Similar stocks